NCT05023655 2026-03-17
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Prisma Health-Upstate
Phase 2 Terminated
Prisma Health-Upstate
Zhejiang University
Nuvation Bio Inc.
BioNTech SE
Boundless Bio, Inc.
Innovent Biologics (Suzhou) Co. Ltd.
Gustave Roussy, Cancer Campus, Grand Paris
Eli Lilly and Company
Sanofi
MapKure, LLC
BioNTech SE
Ono Pharmaceutical Co. Ltd
Memorial Sloan Kettering Cancer Center
Noile-Immune Biotech, Inc
Gilead Sciences
BeiGene
Health Hope Pharma